The potential antidiabetic properties of green and purple tea [Camellia sinensis (L.) O Kuntze], purple tea ellagitannins, and urolithins.
Camellia sinensis
Cellular glucose uptake
Cellular lipid accumulation
Traditional medicine
Type 2 diabetes
α-glucosidase inhibition
Journal
Journal of ethnopharmacology
ISSN: 1872-7573
Titre abrégé: J Ethnopharmacol
Pays: Ireland
ID NLM: 7903310
Informations de publication
Date de publication:
12 Jun 2023
12 Jun 2023
Historique:
received:
27
02
2023
accepted:
07
03
2023
pubmed:
13
3
2023
medline:
28
3
2023
entrez:
12
3
2023
Statut:
ppublish
Résumé
Tea (Camellia sinensis) has been consumed for centuries as traditional medicine for various diseases, including diabetes. The mechanism of action of many traditional medicines, including tea, often requires elucidation. Purple tea is a natural mutant of Camellia sinensis, grown in China and Kenya, and is rich in anthocyanins and ellagitannins. Here we aimed to determine whether commercial green and purple teas are a source of ellagitannins and whether green and purple teas, purple tea ellagitannins and their metabolites urolithins have antidiabetic activity. Targeted UPLC-MS/MS was employed to quantify the ellagitannins corilagin, strictinin and tellimagrandin I, in commercial teas. The inhibitory effect of commercial green and purple teas and purple tea ellagitannins was evaluated on α-glucosidase and α-amylase. The bioavailable urolithins were then investigated for additional antidiabetic effects, by evaluating their effect on cellular glucose uptake and lipid accumulation. Corilagin, strictinin and tellimagrandin I (ellagitannins) were identified as potent inhibitors of α-amylase and α-glucosidase, with K This study identified green-purple teas as an affordable widely available natural source with antidiabetic properties. Furthermore, additional antidiabetic effects of purple tea ellagitannins (corilagin, strictinin and tellimagrandin I) and urolithins were identified.
Identifiants
pubmed: 36907477
pii: S0378-8741(23)00245-3
doi: 10.1016/j.jep.2023.116377
pii:
doi:
Substances chimiques
corilagin
62LOS9TW6D
Hydrolyzable Tannins
0
Hypoglycemic Agents
0
strictinin
0
Tea
0
tellimagrandin I
79786-08-6
urolithin B
0
3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one
1143-70-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
116377Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.